Search

Your search keyword '"Pomerantz, Mark M."' showing total 444 results
Start Over Author "Pomerantz, Mark M."
444 results on '"Pomerantz, Mark M."'

2. Liquid biopsy epigenomic profiling for cancer subtyping

Author

Baca, Sylvan C., Seo, Ji-Heui, Davidsohn, Matthew P., Fortunato, Brad, Semaan, Karl, Sotudian, Shahabbedin, Lakshminarayanan, Gitanjali, Diossy, Miklos, Qiu, Xintao, El Zarif, Talal, Savignano, Hunter, Canniff, John, Madueke, Ikenna, Saliby, Renee Maria, Zhang, Ziwei, Li, Rong, Jiang, Yijia, Taing, Len, Awad, Mark, Chau, Cindy H., DeCaprio, James A., Figg, William D., Greten, Tim F., Hata, Aaron N., Hodi, F. Stephen, Hughes, Melissa E., Ligon, Keith L., Lin, Nancy, Ng, Kimmie, Oser, Matthew G., Meador, Catherine, Parsons, Heather A., Pomerantz, Mark M., Rajan, Arun, Ritz, Jerome, Thakuria, Manisha, Tolaney, Sara M., Wen, Patrick Y., Long, Henry, Berchuck, Jacob E., Szallasi, Zoltan, Choueiri, Toni K., and Freedman, Matthew L.

Published
2023
Full Text
View/download PDF

3. Genetic determinants of chromatin reveal prostate cancer risk mediated by context-dependent gene regulation

Author

Baca, Sylvan C, Singler, Cassandra, Zacharia, Soumya, Seo, Ji-Heui, Morova, Tunc, Hach, Faraz, Ding, Yi, Schwarz, Tommer, Huang, Chia-Chi Flora, Anderson, Jacob, Fay, André P, Kalita, Cynthia, Groha, Stefan, Pomerantz, Mark M, Wang, Victoria, Linder, Simon, Sweeney, Christopher J, Zwart, Wilbert, Lack, Nathan A, Pasaniuc, Bogdan, Takeda, David Y, Gusev, Alexander, and Freedman, Matthew L

Subjects
Biological Sciences, Genetics, Urologic Diseases, Cancer, Human Genome, Prevention, Aging, Cancer Genomics, Biotechnology, Prostate Cancer, 2.1 Biological and endogenous factors, Chromatin, Gene Expression Regulation, Genetic Predisposition to Disease, Genome-Wide Association Study, Humans, Male, Polymorphism, Single Nucleotide, Prostatic Neoplasms, Quantitative Trait Loci, Medical and Health Sciences, Developmental Biology, Agricultural biotechnology, Bioinformatics and computational biology
Abstract

Many genetic variants affect disease risk by altering context-dependent gene regulation. Such variants are difficult to study mechanistically using current methods that link genetic variation to steady-state gene expression levels, such as expression quantitative trait loci (eQTLs). To address this challenge, we developed the cistrome-wide association study (CWAS), a framework for identifying genotypic and allele-specific effects on chromatin that are also associated with disease. In prostate cancer, CWAS identified regulatory elements and androgen receptor-binding sites that explained the association at 52 of 98 known prostate cancer risk loci and discovered 17 additional risk loci. CWAS implicated key developmental transcription factors in prostate cancer risk that are overlooked by eQTL-based approaches due to context-dependent gene regulation. We experimentally validated associations and demonstrated the extensibility of CWAS to additional epigenomic datasets and phenotypes, including response to prostate cancer treatment. CWAS is a powerful and biologically interpretable paradigm for studying variants that influence traits by affecting transcriptional regulation.

Published
2022

4. Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer.

Author

Baca, Sylvan C, Takeda, David Y, Seo, Ji-Heui, Hwang, Justin, Ku, Sheng Yu, Arafeh, Rand, Arnoff, Taylor, Agarwal, Supreet, Bell, Connor, O'Connor, Edward, Qiu, Xintao, Alaiwi, Sarah Abou, Corona, Rosario I, Fonseca, Marcos AS, Giambartolomei, Claudia, Cejas, Paloma, Lim, Klothilda, He, Monica, Sheahan, Anjali, Nassar, Amin, Berchuck, Jacob E, Brown, Lisha, Nguyen, Holly M, Coleman, Ilsa M, Kaipainen, Arja, De Sarkar, Navonil, Nelson, Peter S, Morrissey, Colm, Korthauer, Keegan, Pomerantz, Mark M, Ellis, Leigh, Pasaniuc, Bogdan, Lawrenson, Kate, Kelly, Kathleen, Zoubeidi, Amina, Hahn, William C, Beltran, Himisha, Long, Henry W, Brown, Myles, Corey, Eva, and Freedman, Matthew L

Subjects
Cell Line, Tumor, Animals, Humans, Neuroendocrine Tumors, Adenocarcinoma, Prostatic Neoplasms, Disease Progression, Receptors, Androgen, Gene Expression Regulation, Neoplastic, RNA Interference, Mutation, Male, Hepatocyte Nuclear Factor 3-alpha, Epigenomics, Cell Line, Tumor, Receptors, Androgen, Gene Expression Regulation, Neoplastic
Abstract

Lineage plasticity, the ability of a cell to alter its identity, is an increasingly common mechanism of adaptive resistance to targeted therapy in cancer. An archetypal example is the development of neuroendocrine prostate cancer (NEPC) after treatment of prostate adenocarcinoma (PRAD) with inhibitors of androgen signaling. NEPC is an aggressive variant of prostate cancer that aberrantly expresses genes characteristic of neuroendocrine (NE) tissues and no longer depends on androgens. Here, we investigate the epigenomic basis of this resistance mechanism by profiling histone modifications in NEPC and PRAD patient-derived xenografts (PDXs) using chromatin immunoprecipitation and sequencing (ChIP-seq). We identify a vast network of cis-regulatory elements (N~15,000) that are recurrently activated in NEPC. The FOXA1 transcription factor (TF), which pioneers androgen receptor (AR) chromatin binding in the prostate epithelium, is reprogrammed to NE-specific regulatory elements in NEPC. Despite loss of dependence upon AR, NEPC maintains FOXA1 expression and requires FOXA1 for proliferation and expression of NE lineage-defining genes. Ectopic expression of the NE lineage TFs ASCL1 and NKX2-1 in PRAD cells reprograms FOXA1 to bind to NE regulatory elements and induces enhancer activity as evidenced by histone modifications at these sites. Our data establish the importance of FOXA1 in NEPC and provide a principled approach to identifying cancer dependencies through epigenomic profiling.

Published
2021

5. Author Correction: Liquid biopsy epigenomic profiling for cancer subtyping

Author

Baca, Sylvan C., Seo, Ji-Heui, Davidsohn, Matthew P., Fortunato, Brad, Semaan, Karl, Sotudian, Shahabbedin, Lakshminarayanan, Gitanjali, Diossy, Miklos, Qiu, Xintao, El Zarif, Talal, Savignano, Hunter, Canniff, John, Madueke, Ikenna, Saliby, Renee Maria, Zhang, Ziwei, Li, Rong, Jiang, Yijia, Taing, Len, Awad, Mark, Chau, Cindy H., DeCaprio, James A., Figg, William D., Greten, Tim F., Hata, Aaron N., Hodi, F. Stephen, Hughes, Melissa E., Ligon, Keith L., Lin, Nancy, Ng, Kimmie, Oser, Matthew G., Meador, Catherine, Parsons, Heather A., Pomerantz, Mark M., Rajan, Arun, Ritz, Jerome, Thakuria, Manisha, Tolaney, Sara M., Wen, Patrick Y., Long, Henry, Berchuck, Jacob E., Szallasi, Zoltan, Choueiri, Toni K., and Freedman, Matthew L.

Published
2024
Full Text
View/download PDF

6. Prostate cancer reactivates developmental epigenomic programs during metastatic progression

Author

Pomerantz, Mark M, Qiu, Xintao, Zhu, Yanyun, Takeda, David Y, Pan, Wenting, Baca, Sylvan C, Gusev, Alexander, Korthauer, Keegan D, Severson, Tesa M, Ha, Gavin, Viswanathan, Srinivas R, Seo, Ji-Heui, Nguyen, Holly M, Zhang, Baohui, Pasaniuc, Bogdan, Giambartolomei, Claudia, Alaiwi, Sarah A, Bell, Connor A, O’Connor, Edward P, Chabot, Matthew S, Stillman, David R, Lis, Rosina, Font-Tello, Alba, Li, Lewyn, Cejas, Paloma, Bergman, Andries M, Sanders, Joyce, van der Poel, Henk G, Gayther, Simon A, Lawrenson, Kate, Fonseca, Marcos AS, Reddy, Jessica, Corona, Rosario I, Martovetsky, Gleb, Egan, Brian, Choueiri, Toni, Ellis, Leigh, Garraway, Isla P, Lee, Gwo-Shu Mary, Corey, Eva, Long, Henry W, Zwart, Wilbert, and Freedman, Matthew L

Subjects
Agricultural, Veterinary and Food Sciences, Biological Sciences, Bioinformatics and Computational Biology, Genetics, Agricultural Biotechnology, Aging, Human Genome, Urologic Diseases, Cancer, Prostate Cancer, 2.1 Biological and endogenous factors, Aetiology, Cell Line, Cell Line, Tumor, Disease Progression, Epigenomics, Gene Expression Regulation, Neoplastic, HEK293 Cells, Hepatocyte Nuclear Factor 3-alpha, Humans, Male, Prostate, Prostatic Neoplasms, Receptors, Androgen, Regulatory Sequences, Nucleic Acid, Medical and Health Sciences, Developmental Biology, Agricultural biotechnology, Bioinformatics and computational biology
Abstract

Epigenetic processes govern prostate cancer (PCa) biology, as evidenced by the dependency of PCa cells on the androgen receptor (AR), a prostate master transcription factor. We generated 268 epigenomic datasets spanning two state transitions-from normal prostate epithelium to localized PCa to metastases-in specimens derived from human tissue. We discovered that reprogrammed AR sites in metastatic PCa are not created de novo; rather, they are prepopulated by the transcription factors FOXA1 and HOXB13 in normal prostate epithelium. Reprogrammed regulatory elements commissioned in metastatic disease hijack latent developmental programs, accessing sites that are implicated in prostate organogenesis. Analysis of reactivated regulatory elements enabled the identification and functional validation of previously unknown metastasis-specific enhancers at HOXB13, FOXA1 and NKX3-1. Finally, we observed that prostate lineage-specific regulatory elements were strongly associated with PCa risk heritability and somatic mutation density. Examining prostate biology through an epigenomic lens is fundamental for understanding the mechanisms underlying tumor progression.

Published
2020

7. Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis

Author

Sandler, Kiri A, Cook, Ryan R, Ciezki, Jay P, Ross, Ashley E, Pomerantz, Mark M, Nguyen, Paul L, Shaikh, Talha, Tran, Phuoc T, Stock, Richard G, Merrick, Gregory S, Demanes, David Jeffrey, Spratt, Daniel E, Abu-Isa, Eyad I, Wedde, Trude B, Lilleby, Wolfgang, Krauss, Daniel J, Shaw, Grace K, Alam, Ridwan, Reddy, Chandana A, Song, Daniel Y, Klein, Eric A, Stephenson, Andrew J, Tosoian, Jeffrey J, Hegde, John V, Yoo, Sun Mi, Fiano, Ryan, D'Amico, Anthony V, Nickols, Nicholas G, Aronson, William J, Sadeghi, Ahmad, Greco, Stephen C, Deville, Curtiland, McNutt, Todd, DeWeese, Theodore L, Reiter, Robert E, Said, Jonathan W, Steinberg, Michael L, Horwitz, Eric M, Kupelian, Patrick A, King, Christopher R, and Kishan, Amar U

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Prostate Cancer, Cancer, Aging, Clinical Research, Urologic Diseases, Radiation Oncology, Aged, Brachytherapy, Hemibody Irradiation, Humans, Male, Neoplasm Grading, Pelvis, Prostate, Prostatic Neoplasms, Retrospective Studies, Survival Rate, Gleason grade group 5, Prostate cancer, Radiation therapy, Whole-pelvis irradiation, Urology & Nephrology, Clinical sciences
Abstract

BackgroundThe role of elective whole-pelvis radiotherapy (WPRT) remains controversial. Few studies have investigated it in Gleason grade group (GG) 5 prostate cancer (PCa), known to have a high risk of nodal metastases.ObjectiveTo assess the impact of WPRT on patients with GG 5 PCa treated with external-beam radiotherapy (EBRT) or EBRT with a brachytherapy boost (EBRT+BT).Design, setting, and participantsWe identified 1170 patients with biopsy-proven GG 5 PCa from 11 centers in the United States and one in Norway treated between 2000 and 2013 (734 with EBRT and 436 with EBRT+BT).Outcome measurements and statistical analysisBiochemical recurrence-free survival (bRFS), distant metastasis-free survival (DMFS), and prostate cancer-specific survival (PCSS) were compared using Cox proportional hazards models with propensity score adjustment.Results and limitationsA total of 299 EBRT patients (41%) and 320 EBRT+BT patients (73%) received WPRT. The adjusted 5-yr bRFS rates with WPRT in the EBRT and EBRT+BT groups were 66% and 88%, respectively. Without WPRT, these rates for the EBRT and EBRT+BT groups were 58% and 78%, respectively. The median follow-up was 5.6yr. WPRT was associated with improved bRFS among patients treated with EBRT+BT (hazard ratio [HR] 0.5, 95% confidence interval [CI] 0.2-0.9, p=0.02), but no evidence for improvement was found in those treated with EBRT (HR 0.8, 95% CI 0.6-1.2, p=0.4). WPRT was not significantly associated with improved DMFS or PCSS in the EBRT group (HR 1.1, 95% CI 0.7-1.7, p=0.8 for DMFS and HR 0.7, 95% CI 0.4-1.1, p=0.1 for PCSS), or in the EBRT+BT group (HR 0.6, 95% CI 0.3-1.4, p=0.2 for DMFS and HR 0.5 95% CI 0.2-1.2, p=0.1 for PCSS).ConclusionsWPRT was not associated with improved PCSS or DMFS in patients with GG 5 PCa who received either EBRT or EBRT+BT. However, WPRT was associated with a significant improvement in bRFS among patients receiving EBRT+BT. Strategies to optimize WPRT, potentially with the use of advanced imaging techniques to identify occult nodal disease, are warranted.Patient summaryWhen men with a high Gleason grade prostate cancer receive radiation with external radiation and brachytherapy, the addition of radiation to the pelvis results in a longer duration of prostate-specific antigen control. However, we did not find a difference in their survival from prostate cancer or in their survival without metastatic disease. We also did not find a benefit for radiation to the pelvis in men who received radiation without brachytherapy.

Published
2020

8. Genome-wide germline correlates of the epigenetic landscape of prostate cancer

Author

Houlahan, Kathleen E, Shiah, Yu-Jia, Gusev, Alexander, Yuan, Jiapei, Ahmed, Musaddeque, Shetty, Anamay, Ramanand, Susmita G, Yao, Cindy Q, Bell, Connor, O’Connor, Edward, Huang, Vincent, Fraser, Michael, Heisler, Lawrence E, Livingstone, Julie, Yamaguchi, Takafumi N, Rouette, Alexandre, Foucal, Adrien, Espiritu, Shadrielle Melijah G, Sinha, Ankit, Sam, Michelle, Timms, Lee, Johns, Jeremy, Wong, Ada, Murison, Alex, Orain, Michèle, Picard, Valérie, Hovington, Hélène, Bergeron, Alain, Lacombe, Louis, Lupien, Mathieu, Fradet, Yves, Têtu, Bernard, McPherson, John D, Pasaniuc, Bogdan, Kislinger, Thomas, Chua, Melvin LK, Pomerantz, Mark M, van der Kwast, Theodorus, Freedman, Matthew L, Mani, Ram S, He, Housheng H, Bristow, Robert G, and Boutros, Paul C

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Cancer Genomics, Prostate Cancer, Human Genome, Urologic Diseases, Genetics, 2.1 Biological and endogenous factors, DNA Methylation, Epigenome, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Genetic Predisposition to Disease, Genome, Human, Germ-Line Mutation, Humans, Male, Neoplasm Recurrence, Local, Prostatic Neoplasms, Proto-Oncogene Proteins c-akt, Quantitative Trait Loci, Medical and Health Sciences, Immunology, Biomedical and clinical sciences, Health sciences
Abstract

Oncogenesis is driven by germline, environmental and stochastic factors. It is unknown how these interact to produce the molecular phenotypes of tumors. We therefore quantified the influence of germline polymorphisms on the somatic epigenome of 589 localized prostate tumors. Predisposition risk loci influence a tumor's epigenome, uncovering a mechanism for cancer susceptibility. We identified and validated 1,178 loci associated with altered methylation in tumoral but not nonmalignant tissue. These tumor methylation quantitative trait loci influence chromatin structure, as well as RNA and protein abundance. One prominent tumor methylation quantitative trait locus is associated with AKT1 expression and is predictive of relapse after definitive local therapy in both discovery and validation cohorts. These data reveal intricate crosstalk between the germ line and the epigenome of primary tumors, which may help identify germline biomarkers of aggressive disease to aid patient triage and optimize the use of more invasive or expensive diagnostic assays.

Published
2019

9. MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets

Author

Qiu, Xintao, Boufaied, Nadia, Hallal, Tarek, Feit, Avery, de Polo, Anna, Luoma, Adrienne M., Alahmadi, Walaa, Larocque, Janie, Zadra, Giorgia, Xie, Yingtian, Gu, Shengqing, Tang, Qin, Zhang, Yi, Syamala, Sudeepa, Seo, Ji-Heui, Bell, Connor, O’Connor, Edward, Liu, Yang, Schaeffer, Edward M., Jeffrey Karnes, R., Weinmann, Sheila, Davicioni, Elai, Morrissey, Colm, Cejas, Paloma, Ellis, Leigh, Loda, Massimo, Wucherpfennig, Kai W., Pomerantz, Mark M., Spratt, Daniel E., Corey, Eva, Freedman, Matthew L., Shirley Liu, X., Brown, Myles, Long, Henry W., and Labbé, David P.

Published
2022
Full Text
View/download PDF

11. Supplemental Figure 2 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Author

Choudhury, Atish D., primary, Kwak, Lucia, primary, Cheung, Alexander, primary, Allaire, Kathryn M., primary, Marquez, Jaqueline, primary, Yang, David D., primary, Tripathi, Abhishek, primary, Kilar, Jacqueline M., primary, Flynn, Meredith, primary, Maynard, Brianna, primary, Reichel, Rebecca, primary, Pace, Amanda F., primary, Chen, Brandon K., primary, Van Allen, Eliezer M., primary, Kilbridge, Kerry, primary, Wei, Xiao X., primary, McGregor, Bradley A., primary, Pomerantz, Mark M., primary, Bhatt, Rupal S., primary, Sweeney, Christopher J., primary, Bubley, Glenn J., primary, Jacene, Heather A., primary, Taplin, Mary-Ellen, primary, Huang, Franklin W., primary, Harshman, Lauren C., primary, and Fong, Lawrence, primary

Published
2024
Full Text
View/download PDF

12. Data from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Author

Choudhury, Atish D., primary, Kwak, Lucia, primary, Cheung, Alexander, primary, Allaire, Kathryn M., primary, Marquez, Jaqueline, primary, Yang, David D., primary, Tripathi, Abhishek, primary, Kilar, Jacqueline M., primary, Flynn, Meredith, primary, Maynard, Brianna, primary, Reichel, Rebecca, primary, Pace, Amanda F., primary, Chen, Brandon K., primary, Van Allen, Eliezer M., primary, Kilbridge, Kerry, primary, Wei, Xiao X., primary, McGregor, Bradley A., primary, Pomerantz, Mark M., primary, Bhatt, Rupal S., primary, Sweeney, Christopher J., primary, Bubley, Glenn J., primary, Jacene, Heather A., primary, Taplin, Mary-Ellen, primary, Huang, Franklin W., primary, Harshman, Lauren C., primary, and Fong, Lawrence, primary

Published
2024
Full Text
View/download PDF

13. Supplemental Table 5 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Author

Choudhury, Atish D., primary, Kwak, Lucia, primary, Cheung, Alexander, primary, Allaire, Kathryn M., primary, Marquez, Jaqueline, primary, Yang, David D., primary, Tripathi, Abhishek, primary, Kilar, Jacqueline M., primary, Flynn, Meredith, primary, Maynard, Brianna, primary, Reichel, Rebecca, primary, Pace, Amanda F., primary, Chen, Brandon K., primary, Van Allen, Eliezer M., primary, Kilbridge, Kerry, primary, Wei, Xiao X., primary, McGregor, Bradley A., primary, Pomerantz, Mark M., primary, Bhatt, Rupal S., primary, Sweeney, Christopher J., primary, Bubley, Glenn J., primary, Jacene, Heather A., primary, Taplin, Mary-Ellen, primary, Huang, Franklin W., primary, Harshman, Lauren C., primary, and Fong, Lawrence, primary

Published
2024
Full Text
View/download PDF

14. Supplemental Figure 4 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Author

Choudhury, Atish D., primary, Kwak, Lucia, primary, Cheung, Alexander, primary, Allaire, Kathryn M., primary, Marquez, Jaqueline, primary, Yang, David D., primary, Tripathi, Abhishek, primary, Kilar, Jacqueline M., primary, Flynn, Meredith, primary, Maynard, Brianna, primary, Reichel, Rebecca, primary, Pace, Amanda F., primary, Chen, Brandon K., primary, Van Allen, Eliezer M., primary, Kilbridge, Kerry, primary, Wei, Xiao X., primary, McGregor, Bradley A., primary, Pomerantz, Mark M., primary, Bhatt, Rupal S., primary, Sweeney, Christopher J., primary, Bubley, Glenn J., primary, Jacene, Heather A., primary, Taplin, Mary-Ellen, primary, Huang, Franklin W., primary, Harshman, Lauren C., primary, and Fong, Lawrence, primary

Published
2024
Full Text
View/download PDF

15. Supplemental Table 3 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Author

Choudhury, Atish D., primary, Kwak, Lucia, primary, Cheung, Alexander, primary, Allaire, Kathryn M., primary, Marquez, Jaqueline, primary, Yang, David D., primary, Tripathi, Abhishek, primary, Kilar, Jacqueline M., primary, Flynn, Meredith, primary, Maynard, Brianna, primary, Reichel, Rebecca, primary, Pace, Amanda F., primary, Chen, Brandon K., primary, Van Allen, Eliezer M., primary, Kilbridge, Kerry, primary, Wei, Xiao X., primary, McGregor, Bradley A., primary, Pomerantz, Mark M., primary, Bhatt, Rupal S., primary, Sweeney, Christopher J., primary, Bubley, Glenn J., primary, Jacene, Heather A., primary, Taplin, Mary-Ellen, primary, Huang, Franklin W., primary, Harshman, Lauren C., primary, and Fong, Lawrence, primary

Published
2024
Full Text
View/download PDF

16. Supplemental Figure 1 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Author

Choudhury, Atish D., primary, Kwak, Lucia, primary, Cheung, Alexander, primary, Allaire, Kathryn M., primary, Marquez, Jaqueline, primary, Yang, David D., primary, Tripathi, Abhishek, primary, Kilar, Jacqueline M., primary, Flynn, Meredith, primary, Maynard, Brianna, primary, Reichel, Rebecca, primary, Pace, Amanda F., primary, Chen, Brandon K., primary, Van Allen, Eliezer M., primary, Kilbridge, Kerry, primary, Wei, Xiao X., primary, McGregor, Bradley A., primary, Pomerantz, Mark M., primary, Bhatt, Rupal S., primary, Sweeney, Christopher J., primary, Bubley, Glenn J., primary, Jacene, Heather A., primary, Taplin, Mary-Ellen, primary, Huang, Franklin W., primary, Harshman, Lauren C., primary, and Fong, Lawrence, primary

Published
2024
Full Text
View/download PDF

17. Supplemental Table 1 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Author

Choudhury, Atish D., primary, Kwak, Lucia, primary, Cheung, Alexander, primary, Allaire, Kathryn M., primary, Marquez, Jaqueline, primary, Yang, David D., primary, Tripathi, Abhishek, primary, Kilar, Jacqueline M., primary, Flynn, Meredith, primary, Maynard, Brianna, primary, Reichel, Rebecca, primary, Pace, Amanda F., primary, Chen, Brandon K., primary, Van Allen, Eliezer M., primary, Kilbridge, Kerry, primary, Wei, Xiao X., primary, McGregor, Bradley A., primary, Pomerantz, Mark M., primary, Bhatt, Rupal S., primary, Sweeney, Christopher J., primary, Bubley, Glenn J., primary, Jacene, Heather A., primary, Taplin, Mary-Ellen, primary, Huang, Franklin W., primary, Harshman, Lauren C., primary, and Fong, Lawrence, primary

Published
2024
Full Text
View/download PDF

18. Supplemental Figure 6 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Author

Choudhury, Atish D., primary, Kwak, Lucia, primary, Cheung, Alexander, primary, Allaire, Kathryn M., primary, Marquez, Jaqueline, primary, Yang, David D., primary, Tripathi, Abhishek, primary, Kilar, Jacqueline M., primary, Flynn, Meredith, primary, Maynard, Brianna, primary, Reichel, Rebecca, primary, Pace, Amanda F., primary, Chen, Brandon K., primary, Van Allen, Eliezer M., primary, Kilbridge, Kerry, primary, Wei, Xiao X., primary, McGregor, Bradley A., primary, Pomerantz, Mark M., primary, Bhatt, Rupal S., primary, Sweeney, Christopher J., primary, Bubley, Glenn J., primary, Jacene, Heather A., primary, Taplin, Mary-Ellen, primary, Huang, Franklin W., primary, Harshman, Lauren C., primary, and Fong, Lawrence, primary

Published
2024
Full Text
View/download PDF

19. Supplemental Figure 8 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Author

Choudhury, Atish D., primary, Kwak, Lucia, primary, Cheung, Alexander, primary, Allaire, Kathryn M., primary, Marquez, Jaqueline, primary, Yang, David D., primary, Tripathi, Abhishek, primary, Kilar, Jacqueline M., primary, Flynn, Meredith, primary, Maynard, Brianna, primary, Reichel, Rebecca, primary, Pace, Amanda F., primary, Chen, Brandon K., primary, Van Allen, Eliezer M., primary, Kilbridge, Kerry, primary, Wei, Xiao X., primary, McGregor, Bradley A., primary, Pomerantz, Mark M., primary, Bhatt, Rupal S., primary, Sweeney, Christopher J., primary, Bubley, Glenn J., primary, Jacene, Heather A., primary, Taplin, Mary-Ellen, primary, Huang, Franklin W., primary, Harshman, Lauren C., primary, and Fong, Lawrence, primary

Published
2024
Full Text
View/download PDF

20. Supplemental Table 6 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Author

Choudhury, Atish D., primary, Kwak, Lucia, primary, Cheung, Alexander, primary, Allaire, Kathryn M., primary, Marquez, Jaqueline, primary, Yang, David D., primary, Tripathi, Abhishek, primary, Kilar, Jacqueline M., primary, Flynn, Meredith, primary, Maynard, Brianna, primary, Reichel, Rebecca, primary, Pace, Amanda F., primary, Chen, Brandon K., primary, Van Allen, Eliezer M., primary, Kilbridge, Kerry, primary, Wei, Xiao X., primary, McGregor, Bradley A., primary, Pomerantz, Mark M., primary, Bhatt, Rupal S., primary, Sweeney, Christopher J., primary, Bubley, Glenn J., primary, Jacene, Heather A., primary, Taplin, Mary-Ellen, primary, Huang, Franklin W., primary, Harshman, Lauren C., primary, and Fong, Lawrence, primary

Published
2024
Full Text
View/download PDF

21. Supplemental Figure 7 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Author

Choudhury, Atish D., primary, Kwak, Lucia, primary, Cheung, Alexander, primary, Allaire, Kathryn M., primary, Marquez, Jaqueline, primary, Yang, David D., primary, Tripathi, Abhishek, primary, Kilar, Jacqueline M., primary, Flynn, Meredith, primary, Maynard, Brianna, primary, Reichel, Rebecca, primary, Pace, Amanda F., primary, Chen, Brandon K., primary, Van Allen, Eliezer M., primary, Kilbridge, Kerry, primary, Wei, Xiao X., primary, McGregor, Bradley A., primary, Pomerantz, Mark M., primary, Bhatt, Rupal S., primary, Sweeney, Christopher J., primary, Bubley, Glenn J., primary, Jacene, Heather A., primary, Taplin, Mary-Ellen, primary, Huang, Franklin W., primary, Harshman, Lauren C., primary, and Fong, Lawrence, primary

Published
2024
Full Text
View/download PDF

22. Supplemental Table 2 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Author

Choudhury, Atish D., primary, Kwak, Lucia, primary, Cheung, Alexander, primary, Allaire, Kathryn M., primary, Marquez, Jaqueline, primary, Yang, David D., primary, Tripathi, Abhishek, primary, Kilar, Jacqueline M., primary, Flynn, Meredith, primary, Maynard, Brianna, primary, Reichel, Rebecca, primary, Pace, Amanda F., primary, Chen, Brandon K., primary, Van Allen, Eliezer M., primary, Kilbridge, Kerry, primary, Wei, Xiao X., primary, McGregor, Bradley A., primary, Pomerantz, Mark M., primary, Bhatt, Rupal S., primary, Sweeney, Christopher J., primary, Bubley, Glenn J., primary, Jacene, Heather A., primary, Taplin, Mary-Ellen, primary, Huang, Franklin W., primary, Harshman, Lauren C., primary, and Fong, Lawrence, primary

Published
2024
Full Text
View/download PDF

23. Supplementary File 3 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Author

Choudhury, Atish D., primary, Kwak, Lucia, primary, Cheung, Alexander, primary, Allaire, Kathryn M., primary, Marquez, Jaqueline, primary, Yang, David D., primary, Tripathi, Abhishek, primary, Kilar, Jacqueline M., primary, Flynn, Meredith, primary, Maynard, Brianna, primary, Reichel, Rebecca, primary, Pace, Amanda F., primary, Chen, Brandon K., primary, Van Allen, Eliezer M., primary, Kilbridge, Kerry, primary, Wei, Xiao X., primary, McGregor, Bradley A., primary, Pomerantz, Mark M., primary, Bhatt, Rupal S., primary, Sweeney, Christopher J., primary, Bubley, Glenn J., primary, Jacene, Heather A., primary, Taplin, Mary-Ellen, primary, Huang, Franklin W., primary, Harshman, Lauren C., primary, and Fong, Lawrence, primary

Published
2024
Full Text
View/download PDF

24. Supplemental Figure 5 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Author

Choudhury, Atish D., primary, Kwak, Lucia, primary, Cheung, Alexander, primary, Allaire, Kathryn M., primary, Marquez, Jaqueline, primary, Yang, David D., primary, Tripathi, Abhishek, primary, Kilar, Jacqueline M., primary, Flynn, Meredith, primary, Maynard, Brianna, primary, Reichel, Rebecca, primary, Pace, Amanda F., primary, Chen, Brandon K., primary, Van Allen, Eliezer M., primary, Kilbridge, Kerry, primary, Wei, Xiao X., primary, McGregor, Bradley A., primary, Pomerantz, Mark M., primary, Bhatt, Rupal S., primary, Sweeney, Christopher J., primary, Bubley, Glenn J., primary, Jacene, Heather A., primary, Taplin, Mary-Ellen, primary, Huang, Franklin W., primary, Harshman, Lauren C., primary, and Fong, Lawrence, primary

Published
2024
Full Text
View/download PDF

25. Supplemental Table 4 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Author

Choudhury, Atish D., primary, Kwak, Lucia, primary, Cheung, Alexander, primary, Allaire, Kathryn M., primary, Marquez, Jaqueline, primary, Yang, David D., primary, Tripathi, Abhishek, primary, Kilar, Jacqueline M., primary, Flynn, Meredith, primary, Maynard, Brianna, primary, Reichel, Rebecca, primary, Pace, Amanda F., primary, Chen, Brandon K., primary, Van Allen, Eliezer M., primary, Kilbridge, Kerry, primary, Wei, Xiao X., primary, McGregor, Bradley A., primary, Pomerantz, Mark M., primary, Bhatt, Rupal S., primary, Sweeney, Christopher J., primary, Bubley, Glenn J., primary, Jacene, Heather A., primary, Taplin, Mary-Ellen, primary, Huang, Franklin W., primary, Harshman, Lauren C., primary, and Fong, Lawrence, primary

Published
2024
Full Text
View/download PDF

28. Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Author

Choudhury, Atish D., primary, Kwak, Lucia, additional, Cheung, Alexander, additional, Allaire, Kathryn M., additional, Marquez, Jaqueline, additional, Yang, David D., additional, Tripathi, Abhishek, additional, Kilar, Jacqueline M., additional, Flynn, Meredith, additional, Maynard, Brianna, additional, Reichel, Rebecca, additional, Pace, Amanda F., additional, Chen, Brandon K., additional, Van Allen, Eliezer M., additional, Kilbridge, Kerry, additional, Wei, Xiao X., additional, McGregor, Bradley A., additional, Pomerantz, Mark M., additional, Bhatt, Rupal S., additional, Sweeney, Christopher J., additional, Bubley, Glenn J., additional, Jacene, Heather A., additional, Taplin, Mary-Ellen, additional, Huang, Franklin W., additional, Harshman, Lauren C., additional, and Fong, Lawrence, additional

Published
2024
Full Text
View/download PDF

29. FIGURE 1 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Author

Rencsok, Emily M., primary, Slopen, Natalie, primary, McManus, Hannah D., primary, Autio, Karen A., primary, Morgans, Alicia K., primary, McSwain, Lawrence, primary, Barata, Pedro, primary, Cheng, Heather H., primary, Dreicer, Robert, primary, Gerke, Travis, primary, Green, Rebecca, primary, Heath, Elisabeth I., primary, Howard, Lauren E., primary, McKay, Rana R., primary, Nowak, Joel, primary, Pileggi, Shannon, primary, Pomerantz, Mark M., primary, Rathkopf, Dana E., primary, Tagawa, Scott T., primary, Whang, Young E., primary, Ragin, Camille, primary, Odedina, Folakemi T., primary, Kantoff, Philip W., primary, Vinson, Jake, primary, Villanti, Paul, primary, Haneuse, Sebastien, primary, Mucci, Lorelei A., primary, and George, Daniel J., primary

Published
2024
Full Text
View/download PDF

30. Data from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Author

Rencsok, Emily M., primary, Slopen, Natalie, primary, McManus, Hannah D., primary, Autio, Karen A., primary, Morgans, Alicia K., primary, McSwain, Lawrence, primary, Barata, Pedro, primary, Cheng, Heather H., primary, Dreicer, Robert, primary, Gerke, Travis, primary, Green, Rebecca, primary, Heath, Elisabeth I., primary, Howard, Lauren E., primary, McKay, Rana R., primary, Nowak, Joel, primary, Pileggi, Shannon, primary, Pomerantz, Mark M., primary, Rathkopf, Dana E., primary, Tagawa, Scott T., primary, Whang, Young E., primary, Ragin, Camille, primary, Odedina, Folakemi T., primary, Kantoff, Philip W., primary, Vinson, Jake, primary, Villanti, Paul, primary, Haneuse, Sebastien, primary, Mucci, Lorelei A., primary, and George, Daniel J., primary

Published
2024
Full Text
View/download PDF

31. Data from Marital Status, Living Arrangement, and Survival among Individuals with Advanced Prostate Cancer in the International Registry for Men with Advanced Prostate Cancer

Author

Chen, Naiyu, primary, McGrath, Colleen B., primary, Ericsson, Caroline I., primary, Vaselkiv, Jane B., primary, Rencsok, Emily M., primary, Stopsack, Konrad H., primary, Guard, Hannah E., primary, Autio, Karen A., primary, Rathkopf, Dana E., primary, Enting, Deborah, primary, Bitting, Rhonda L., primary, Mateo, Joaquin, primary, Githiaka, Charles W., primary, Chi, Kim N., primary, Cheng, Heather H., primary, Davis, Ian D., primary, Anderson, Simon G., primary, Badal, Simone Ann Marie, primary, Bjartell, Anders, primary, Russnes, Kjell M., primary, Heath, Elisabeth I., primary, Pomerantz, Mark M., primary, Henegan, John C., primary, Hyslop, Terry, primary, Esteban, Emilio, primary, Omlin, Aurelius, primary, McDermott, Ray, primary, Fay, Andre P., primary, Popoola, Ademola Alabi, primary, Ragin, Camille, primary, Nowak, Joel, primary, Gerke, Travis, primary, Kantoff, Philip W., primary, George, Daniel J., primary, Penney, Kathryn L., primary, and Mucci, Lorelei A., primary

Published
2024
Full Text
View/download PDF

32. Supplementary Table 1. from Marital Status, Living Arrangement, and Survival among Individuals with Advanced Prostate Cancer in the International Registry for Men with Advanced Prostate Cancer

Author

Chen, Naiyu, primary, McGrath, Colleen B., primary, Ericsson, Caroline I., primary, Vaselkiv, Jane B., primary, Rencsok, Emily M., primary, Stopsack, Konrad H., primary, Guard, Hannah E., primary, Autio, Karen A., primary, Rathkopf, Dana E., primary, Enting, Deborah, primary, Bitting, Rhonda L., primary, Mateo, Joaquin, primary, Githiaka, Charles W., primary, Chi, Kim N., primary, Cheng, Heather H., primary, Davis, Ian D., primary, Anderson, Simon G., primary, Badal, Simone Ann Marie, primary, Bjartell, Anders, primary, Russnes, Kjell M., primary, Heath, Elisabeth I., primary, Pomerantz, Mark M., primary, Henegan, John C., primary, Hyslop, Terry, primary, Esteban, Emilio, primary, Omlin, Aurelius, primary, McDermott, Ray, primary, Fay, Andre P., primary, Popoola, Ademola Alabi, primary, Ragin, Camille, primary, Nowak, Joel, primary, Gerke, Travis, primary, Kantoff, Philip W., primary, George, Daniel J., primary, Penney, Kathryn L., primary, and Mucci, Lorelei A., primary

Published
2024
Full Text
View/download PDF

33. EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer

Author

Morel, Katherine L., Sheahan, Anjali V., Burkhart, Deborah L., Baca, Sylvan C., Boufaied, Nadia, Liu, Yin, Qiu, Xintao, Cañadas, Israel, Roehle, Kevin, Heckler, Max, Calagua, Carla, Ye, Huihui, Pantelidou, Constantia, Galbo, Phillip, Panja, Sukanya, Mitrofanova, Antonina, Wilkinson, Scott, Whitlock, Nichelle C., Trostel, Shana Y., Hamid, Anis A., Kibel, Adam S., Barbie, David A., Choudhury, Atish D., Pomerantz, Mark M., Sweeney, Christopher J., Long, Henry W., Einstein, David J., Shapiro, Geoffrey I., Dougan, Stephanie K., Sowalsky, Adam G., He, Housheng Hansen, Freedman, Matthew L., Balk, Steven P., Loda, Massimo, Labbé, David P., Olson, Brian M., and Ellis, Leigh

Published
2021
Full Text
View/download PDF

36. Addition of Germline Testing to Tumor-Only Sequencing Improves Detection of Pathogenic Germline Variants in Men With Advanced Prostate Cancer

Author

Berchuck, Jacob E., Boiarsky, Daniel, Silver, Rebecca, Sunkara, Rajitha, McClure, Heather M., Tsai, Harrison K., Siegmund, Stephanie, Tewari, Alok K., Nowak, Jonathan A., Lindeman, Neal I., Rana, Huma Q., Choudhury, Atish D., Pomerantz, Mark M., Freedman, Matthew L., Van Allen, Eliezer M., and Taplin, Mary-Ellen

Published
2022
Full Text
View/download PDF

37. FIGURE 2 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Author

Rencsok, Emily M., primary, Slopen, Natalie, primary, McManus, Hannah D., primary, Autio, Karen A., primary, Morgans, Alicia K., primary, McSwain, Lawrence, primary, Barata, Pedro, primary, Cheng, Heather H., primary, Dreicer, Robert, primary, Gerke, Travis, primary, Green, Rebecca, primary, Heath, Elisabeth I., primary, Howard, Lauren E., primary, McKay, Rana R., primary, Nowak, Joel, primary, Pileggi, Shannon, primary, Pomerantz, Mark M., primary, Rathkopf, Dana E., primary, Tagawa, Scott T., primary, Whang, Young E., primary, Ragin, Camille, primary, Odedina, Folakemi T., primary, Kantoff, Philip W., primary, Vinson, Jake, primary, Villanti, Paul, primary, Haneuse, Sebastien, primary, Mucci, Lorelei A., primary, and George, Daniel J., primary

Published
2024
Full Text
View/download PDF

38. Supplementary Table S4 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Author

Rencsok, Emily M., primary, Slopen, Natalie, primary, McManus, Hannah D., primary, Autio, Karen A., primary, Morgans, Alicia K., primary, McSwain, Lawrence, primary, Barata, Pedro, primary, Cheng, Heather H., primary, Dreicer, Robert, primary, Gerke, Travis, primary, Green, Rebecca, primary, Heath, Elisabeth I., primary, Howard, Lauren E., primary, McKay, Rana R., primary, Nowak, Joel, primary, Pileggi, Shannon, primary, Pomerantz, Mark M., primary, Rathkopf, Dana E., primary, Tagawa, Scott T., primary, Whang, Young E., primary, Ragin, Camille, primary, Odedina, Folakemi T., primary, Kantoff, Philip W., primary, Vinson, Jake, primary, Villanti, Paul, primary, Haneuse, Sebastien, primary, Mucci, Lorelei A., primary, and George, Daniel J., primary

Published
2024
Full Text
View/download PDF

39. Supplementary Figure S2 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Author

Rencsok, Emily M., primary, Slopen, Natalie, primary, McManus, Hannah D., primary, Autio, Karen A., primary, Morgans, Alicia K., primary, McSwain, Lawrence, primary, Barata, Pedro, primary, Cheng, Heather H., primary, Dreicer, Robert, primary, Gerke, Travis, primary, Green, Rebecca, primary, Heath, Elisabeth I., primary, Howard, Lauren E., primary, McKay, Rana R., primary, Nowak, Joel, primary, Pileggi, Shannon, primary, Pomerantz, Mark M., primary, Rathkopf, Dana E., primary, Tagawa, Scott T., primary, Whang, Young E., primary, Ragin, Camille, primary, Odedina, Folakemi T., primary, Kantoff, Philip W., primary, Vinson, Jake, primary, Villanti, Paul, primary, Haneuse, Sebastien, primary, Mucci, Lorelei A., primary, and George, Daniel J., primary

Published
2024
Full Text
View/download PDF

40. TABLE 1 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Author

Rencsok, Emily M., primary, Slopen, Natalie, primary, McManus, Hannah D., primary, Autio, Karen A., primary, Morgans, Alicia K., primary, McSwain, Lawrence, primary, Barata, Pedro, primary, Cheng, Heather H., primary, Dreicer, Robert, primary, Gerke, Travis, primary, Green, Rebecca, primary, Heath, Elisabeth I., primary, Howard, Lauren E., primary, McKay, Rana R., primary, Nowak, Joel, primary, Pileggi, Shannon, primary, Pomerantz, Mark M., primary, Rathkopf, Dana E., primary, Tagawa, Scott T., primary, Whang, Young E., primary, Ragin, Camille, primary, Odedina, Folakemi T., primary, Kantoff, Philip W., primary, Vinson, Jake, primary, Villanti, Paul, primary, Haneuse, Sebastien, primary, Mucci, Lorelei A., primary, and George, Daniel J., primary

Published
2024
Full Text
View/download PDF

41. TABLE 3 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Author

Rencsok, Emily M., primary, Slopen, Natalie, primary, McManus, Hannah D., primary, Autio, Karen A., primary, Morgans, Alicia K., primary, McSwain, Lawrence, primary, Barata, Pedro, primary, Cheng, Heather H., primary, Dreicer, Robert, primary, Gerke, Travis, primary, Green, Rebecca, primary, Heath, Elisabeth I., primary, Howard, Lauren E., primary, McKay, Rana R., primary, Nowak, Joel, primary, Pileggi, Shannon, primary, Pomerantz, Mark M., primary, Rathkopf, Dana E., primary, Tagawa, Scott T., primary, Whang, Young E., primary, Ragin, Camille, primary, Odedina, Folakemi T., primary, Kantoff, Philip W., primary, Vinson, Jake, primary, Villanti, Paul, primary, Haneuse, Sebastien, primary, Mucci, Lorelei A., primary, and George, Daniel J., primary

Published
2024
Full Text
View/download PDF

42. TABLE 4 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Author

Rencsok, Emily M., primary, Slopen, Natalie, primary, McManus, Hannah D., primary, Autio, Karen A., primary, Morgans, Alicia K., primary, McSwain, Lawrence, primary, Barata, Pedro, primary, Cheng, Heather H., primary, Dreicer, Robert, primary, Gerke, Travis, primary, Green, Rebecca, primary, Heath, Elisabeth I., primary, Howard, Lauren E., primary, McKay, Rana R., primary, Nowak, Joel, primary, Pileggi, Shannon, primary, Pomerantz, Mark M., primary, Rathkopf, Dana E., primary, Tagawa, Scott T., primary, Whang, Young E., primary, Ragin, Camille, primary, Odedina, Folakemi T., primary, Kantoff, Philip W., primary, Vinson, Jake, primary, Villanti, Paul, primary, Haneuse, Sebastien, primary, Mucci, Lorelei A., primary, and George, Daniel J., primary

Published
2024
Full Text
View/download PDF

43. TABLE 2 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Author

Rencsok, Emily M., primary, Slopen, Natalie, primary, McManus, Hannah D., primary, Autio, Karen A., primary, Morgans, Alicia K., primary, McSwain, Lawrence, primary, Barata, Pedro, primary, Cheng, Heather H., primary, Dreicer, Robert, primary, Gerke, Travis, primary, Green, Rebecca, primary, Heath, Elisabeth I., primary, Howard, Lauren E., primary, McKay, Rana R., primary, Nowak, Joel, primary, Pileggi, Shannon, primary, Pomerantz, Mark M., primary, Rathkopf, Dana E., primary, Tagawa, Scott T., primary, Whang, Young E., primary, Ragin, Camille, primary, Odedina, Folakemi T., primary, Kantoff, Philip W., primary, Vinson, Jake, primary, Villanti, Paul, primary, Haneuse, Sebastien, primary, Mucci, Lorelei A., primary, and George, Daniel J., primary

Published
2024
Full Text
View/download PDF

44. Marital status, living arrangement, and survival among individuals with advanced prostate cancer in the International Registry for Men with Advanced Prostate Cancer

Author

Chen, Naiyu, primary, McGrath, Colleen B., additional, Ericsson, Caroline I., additional, Vaselkiv, Jane B., additional, Rencsok, Emily M., additional, Stopsack, Konrad H., additional, Guard, Hannah E., additional, Autio, Karen A., additional, Rathkopf, Dana E., additional, Enting, Deborah, additional, Bitting, Rhonda L., additional, Mateo, Joaquin, additional, Githiaka, Charles Waihenya., additional, Chi, Kim N., additional, Cheng, Heather H., additional, Davis, Ian D., additional, Anderson, Simon G., additional, Badal, Simone Ann Marie., additional, Bjartell, Anders, additional, Russnes, Kjell M., additional, Heath, Elisabeth I., additional, Pomerantz, Mark M., additional, Henegan, John C., additional, Hyslop, Terry, additional, Esteban, Emilio, additional, Omlin, Aurelius, additional, McDermott, Ray, additional, Fay, Andre P., additional, Popoola, Ademola Alabi., additional, Ragin, Camille, additional, Nowak, Joel, additional, Gerke, Travis, additional, Kantoff, Philip W., additional, George, Daniel J., additional, Penney, Kathryn L., additional, and Mucci, Lorelei A., additional

Published
2024
Full Text
View/download PDF

45. Supplementary Methods S1 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Author

Rencsok, Emily M., primary, Slopen, Natalie, primary, McManus, Hannah D., primary, Autio, Karen A., primary, Morgans, Alicia K., primary, McSwain, Lawrence, primary, Barata, Pedro, primary, Cheng, Heather H., primary, Dreicer, Robert, primary, Gerke, Travis, primary, Green, Rebecca, primary, Heath, Elisabeth I., primary, Howard, Lauren E., primary, McKay, Rana R., primary, Nowak, Joel, primary, Pileggi, Shannon, primary, Pomerantz, Mark M., primary, Rathkopf, Dana E., primary, Tagawa, Scott T., primary, Whang, Young E., primary, Ragin, Camille, primary, Odedina, Folakemi T., primary, Kantoff, Philip W., primary, Vinson, Jake, primary, Villanti, Paul, primary, Haneuse, Sebastien, primary, Mucci, Lorelei A., primary, and George, Daniel J., primary

Published
2024
Full Text
View/download PDF

46. Postradical prostatectomy prostate‐specific antigen outcomes after 6 versus 18 months of perioperative androgen‐deprivation therapy in men with localized, unfavorable intermediate‐risk or high‐risk prostate cancer: Results of part 2 of a randomized phase 2 trial

Author

McKay, Rana R., Xie, Wanling, Yang, Xiaoyu, Acosta, Andres, Rathkopf, Dana, Laudone, Vincent P., Bubley, Glenn J., Einstein, David J., Chang, Peter, Wagner, Andrew A., Kane, Christopher J., Preston, Mark A., Kilbridge, Kerry, Chang, Steven L., Choudhury, Atish D., Pomerantz, Mark M., Trinh, Quoc‐Dien, Kibel, Adam S., and Taplin, Mary‐Ellen

Subjects
PROSTATE cancer, PROSTATE-specific antigen, PROSTATECTOMY, GLEASON grading system, PATIENT participation, RADICAL prostatectomy, TUMOR classification
Abstract

Background: Patients with localized, unfavorable intermediate–risk and high‐risk prostate cancer have an increased risk of relapse after radical prostatectomy (RP). The authors previously reported on part 1 of this phase 2 trial testing neoadjuvant apalutamide, abiraterone, prednisone, plus leuprolide (AAPL) or abiraterone, prednisone, and leuprolide (APL) for 6 months followed by RP. The results demonstrated favorable pathologic responses (tumor <5 mm) in 20.3% of patients (n = 24 of 118). Herein, the authors report the results of part 2. Methods: For part 2, patients were randomized 1:1 to receive either AAPL for 12 months (arm 2A) or observation (arm 2B), stratified by neoadjuvant therapy and pathologic tumor classification. The primary end point was 3‐year biochemical progression‐free survival. Secondary end points included safety and testosterone recovery (>200 ng/dL). Results: Overall, 82 of 118 patients (69%) enrolled in part 1 were randomized to part 2. A higher proportion of patients who were not randomized to adjuvant therapy had a favorable prostatectomy pathologic response (32.3% in nonrandomized patients compared with 17.1% in randomized patients). In the intent‐to‐treat analysis, the 3‐year biochemical progression‐free survival rate was 81% for arm 2A and 72% for arm 2B (hazard ratio, 0.81; 90% confidence interval, 0.43–1.49). Of the randomized patients, 81% had testosterone recovery in the AAPL group compared with 95% in the observation group, with a median time to recovery of <12 months in both arms. Conclusions: In this study, because 30% of patients declined adjuvant treatment, part B was underpowered to detect differences between arms. Future perioperative studies should be biomarker‐directed and include strategies for investigator and patient engagement to ensure compliance with protocol procedures. This phase 2 study investigated 6 versus 18 months of perioperative androgen‐deprivation therapy in men with localized, unfavorable intermediate‐risk or high‐risk prostate cancer. Because patients dropped out of part 2 randomization postprostatectomy, the study was underpowered to detect differences in 3‐year biochemical progression‐free survival between treatment arms. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

47. Author Correction: Liquid biopsy epigenomic profiling for cancer subtyping

Author

Baca, Sylvan C., primary, Seo, Ji-Heui, additional, Davidsohn, Matthew P., additional, Fortunato, Brad, additional, Semaan, Karl, additional, Sotudian, Shahabbedin, additional, Lakshminarayanan, Gitanjali, additional, Diossy, Miklos, additional, Qiu, Xintao, additional, El Zarif, Talal, additional, Savignano, Hunter, additional, Canniff, John, additional, Madueke, Ikenna, additional, Saliby, Renee Maria, additional, Zhang, Ziwei, additional, Li, Rong, additional, Jiang, Yijia, additional, Taing, Len, additional, Awad, Mark, additional, Chau, Cindy H., additional, DeCaprio, James A., additional, Figg, William D., additional, Greten, Tim F., additional, Hata, Aaron N., additional, Hodi, F. Stephen, additional, Hughes, Melissa E., additional, Ligon, Keith L., additional, Lin, Nancy, additional, Ng, Kimmie, additional, Oser, Matthew G., additional, Meador, Catherine, additional, Parsons, Heather A., additional, Pomerantz, Mark M., additional, Rajan, Arun, additional, Ritz, Jerome, additional, Thakuria, Manisha, additional, Tolaney, Sara M., additional, Wen, Patrick Y., additional, Long, Henry, additional, Berchuck, Jacob E., additional, Szallasi, Zoltan, additional, Choueiri, Toni K., additional, and Freedman, Matthew L., additional

Published
2023
Full Text
View/download PDF

48. Grade Group 1 Prostate Cancers Exhibit Tumor-defining Androgen Receptor–driven Programs

Author

Linder, Simon, primary, Severson, Tesa M., additional, van der Mijn, Koen J.C., additional, Nevedomskaya, Ekaterina, additional, Siefert, Joseph C., additional, Stelloo, Suzan, additional, Pomerantz, Mark M., additional, Freedman, Matthew L., additional, van der Poel, Henk, additional, Jerónimo, Carmen, additional, Henrique, Rui, additional, Bergman, Andries M., additional, and Zwart, Wilbert, additional

Published
2023
Full Text
View/download PDF

49. Pretest Video Education Versus Genetic Counseling for Patients With Prostate Cancer: ProGen, A Multisite Randomized Controlled Trial

Author

Rana, Huma Q., primary, Stopfer, Jill E., additional, Weitz, Michelle, additional, Kipnis, Lindsay, additional, Koeller, Diane R., additional, Culver, Samantha, additional, Mercado, Joanna, additional, Gelman, Rebecca Sue, additional, Underhill-Blazey, Meghan, additional, McGregor, Bradley A., additional, Sweeney, Christopher J., additional, Petrucelli, Nancie, additional, Kokenakes, Courtney, additional, Pirzadeh-Miller, Sara, additional, Reys, Brian, additional, Frazier, Arthur, additional, Knechtl, Andrew, additional, Fateh, Salman, additional, Vatnick, Donna Rachel, additional, Silver, Rebecca, additional, Kilbridge, Kerry E., additional, Pomerantz, Mark M., additional, Wei, Xiao X., additional, Choudhury, Atish D., additional, Sonpavde, Guru P., additional, Kozyreva, Olga, additional, Lathan, Christopher, additional, Horton, Carrie, additional, Dolinsky, Jill S., additional, Heath, Elisabeth I., additional, Ross, Theodora Suzanne, additional, Courtney, Kevin Dale, additional, Garber, Judy E., additional, and Taplin, Mary-Ellen, additional

Published
2023
Full Text
View/download PDF

50. A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate Cancer

Author

Takeda, David Y., Spisák, Sándor, Seo, Ji-Heui, Bell, Connor, O’Connor, Edward, Korthauer, Keegan, Ribli, Dezső, Csabai, István, Solymosi, Norbert, Szállási, Zoltán, Stillman, David R., Cejas, Paloma, Qiu, Xintao, Long, Henry W., Tisza, Viktória, Nuzzo, Pier Vitale, Rohanizadegan, Mersedeh, Pomerantz, Mark M., Hahn, William C., and Freedman, Matthew L.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results